NCT06327295View on ClinicalTrials.gov

A Study of ATB1651 in Adults With Mild to Moderate Onchomycosis

PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

January 30, 2026

Conditions
Onychomycosis
Interventions
DRUG

ATB1651-102- Cohort 1

Dosage form- Topical solution; Dosage- 3% formulation The participants will apply the daily dose of 3% ATB1651 once daily to the affected great toenail for 12 weeks with a follow-up for 24 weeks.

DRUG

ATB1651-102- Cohort 2

Dosage form- Topical solution; Dosage- 3% formulation The participants will apply the daily dose of 3% ATB1651 once daily to the affected great toenail for 20 weeks with a follow-up for 16 weeks.

DRUG

ATB1651-102- Cohort 3

Dosage form- Topical solution; Dosage- 3% formulation The participants will apply the daily dose of 3% ATB1651 twice daily to the affected great toenail for 12 weeks with a follow-up for 24 weeks.

DRUG

ATB1651-102- Cohort 4

Dosage form- Topical solution; Dosage- 5% formulation The participants will apply the daily dose of 5% ATB1651 once daily to the affected great toenail for 12 weeks with a follow-up for 24 weeks.

DRUG

Placebo

participants will receive matching placebo across cohorts 1-4 of the study.

Trial Locations (1)

8011

RECRUITING

New Zealand Clinical Research Christchurch, Christchurch

All Listed Sponsors
lead

AmtixBio Co., Ltd.

INDUSTRY